Acetyl-L-Carnitine in dementia
โ Scribed by Dr. G. A. Livingston; K. B. Sax; Z. McClenahan; E. Blumenthal; K. Foley; J. Willison; A. H. Mann; I. M. James
- Book ID
- 102845959
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 620 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
โฆ Synopsis
This study was designed to test the benefit of acetyl-1-carnitine in patients with dementia. Seventy-one patients of 65 years and over, living in their own homes or in residential care, took part in a 24-week randomized, double-blind, placebo-controlled, parallel-group clinical trial. The outcome was measured by comparing psychometric tests at 24 weeks to baseline measures. The active treatment group improved in mean scores in seven out ofeight psychometric tests, the placebo treatment group in only two out of eight tests. The improvements were statistically significant in one test, recognition memory (p <0.01). Linear discriminant function analysis indicated that active and placebo therapy could be distinguished according to the pattern of responses to the eight psychological tests (p< 0.01). In this small trial, acetyl-I-carnitine was shown to be non-toxic and possibly beneficial. Further large-scale trials are needed over long periods of time.
KEY woms-Acetyl-1-carnitine, drugs, dementia, Alzheimer's disease.
๐ SIMILAR VOLUMES
The neuroprotective properties of acetyl-L-carnitine (ALCAR) were investigated in primary cell cultures from rat hippocampal formation and cerebral cortex of 17-day-old rat embryos. Chronic exposure to ALCAR (10-50 pM for 10 days) reduced the cell mortality induced by 24 hr fetal calf serum deprivat
Acetyl-L-carnitine 1.5 g and 3.0 g was administered as three divided doses on each of two occasions to 24 people with varying renal failure (creatinine clearance 127-8 ml.min-1). Plasma and urinary concentrations of total-L-carnitine, free (non-esterified) carnitine, short-chain esters and acetyl-L-